Sinalax

Quick links to important sections

Sinalax

Method of action: Laxative

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinalax

Property Description
Active Ingredient Lactitol (Monohydrate)
Form Oral Powder for Solution or Syrup
Pharmacological Class Osmotic Laxative / Cathartic
Common Use Aiding bowel function; relieving difficulty with defecation
Origin Synthetic (Sugar Alcohol Derivative)

Sinalax: A Synthetic Osmotic Laxative

Sinalax is a proprietary pharmaceutical preparation primarily known in regions such as Italy and Eastern Europe. It is classified as an Osmotic Laxative, administered orally, and used to help normalize bowel movements. The active compound, Lactitol, is an osmotic agent, which means it works by physically drawing water into the intestinal lumen. This mechanism means the medicine helps to relieve discomfort by softening and hydrating the stool through a natural physical process, a benefit recognized for its gentle action compared to stimulant agents.


What is Lactitol? Composition and Origin

The sole active ingredient in Sinalax is Lactitol, a compound that is chemically defined as a synthetic sugar alcohol derived from lactose. Lactitol is intentionally formulated to be non-absorbable in the upper digestive tract, ensuring that it remains functionally intact until it reaches the colon. This poor absorption allows the agent to exert its full osmotic potential in the lower intestine. Its typical presentation as an easy-to-mix powder positions it for adult patients seeking a simple addition to their daily fluid intake.


General Purpose: How Sinalax Aids Bowel Function

The general purpose of Sinalax is to address the difficulty and discomfort associated with hard, infrequent stools by increasing stool softness and volume. This is achieved because the unabsorbed Lactitol generates its hyperosmotic effect, physically drawing water into the intestinal lumen. Furthermore, Lactitol is subject to bacterial fermentation in the colon, which is associated with a recognized prebiotic effect that contributes to the health of the gut microbiota.

Regulatory References

  1. EMA EPAR

What side effects are possible with Sinalax?

Possible Side Effects and Safety Information

The official safety profile of Sinalax, which contains sennosides, is structured around the potential adverse reactions and regulatory constraints documented by government health authorities, such as the FDA and EMA. This medicine is formally designated for short-term use only.


Adverse Reactions by System and Frequency

The majority of documented adverse reactions relate to the Gastrointestinal System.

  • Common Reactions: The most frequently cited effects, classified as Common in regulatory documents, include abdominal pain, stomach cramps, and diarrhoea.
  • Incidence Not Known: Reactions reported without a defined frequency include pruritus (itching), generalised rash (exanthema), and melanosis coli (benign pigmentation of the large intestine lining, associated with long-term use).

Serious Safety Considerations and Constraints

The regulatory safety profile highlights risks associated with misuse or underlying health status:

  • Electrolyte and Fluid Balance: Prolonged use beyond the recommended short duration increases the documented risk of severe electrolyte imbalance and dehydration. This can potentially lead to laxative dependence or impaired normal bowel function.
  • Serious Reactions: Documented serious adverse events include severe allergic reactions and signs of serious underlying issues such as rectal bleeding.
  • Population Safety: Use is generally not recommended during pregnancy and lactation. Older adults are cited as being at an increased risk of dehydration and electrolyte imbalance and require close observation.
  • Restrictions on Use: Sinalax is contraindicated (should not be used) if conditions such as intestinal obstruction, acute abdominal pain, or severe dehydration are present, as defined in the official regulatory prescribing information.

Overdose and Emergency Response

Overdose with Sinalax (Lactitol) primarily results from the administration of a supra-therapeutic dose. The documented overdose presentations are pronounced gastrointestinal manifestations, including severe diarrhoea, heightened abdominal cramps, and abdominal pain.

The immediate and serious risk is associated with the effect on the Metabolic System. Excessive fluid loss from severe diarrhoea can lead to a critical disturbance of the electrolyte balance. This extensive fluid loss results in potentially severe dehydration and key electrolyte abnormalities, such as hypokalemia (low serum potassium) and hypernatremia (high serum sodium).

Regulatory documentation advises that urgent medical attention is necessitated by symptoms indicative of severe fluid loss or electrolyte disturbance. If these severe manifestations are present, you must seek immediate medical treatment.

The official response requires termination of the medicine upon symptom manifestation. Management is limited to symptomatic and supportive treatment, as no specific antidote is known. Corrective measures must focus primarily on the replacement of fluid loss and the correction of electrolyte disturbances. Elderly or debilitated patients are specifically noted as requiring close monitoring of serum electrolytes during an overdose event due to their increased vulnerability to severe imbalance.

Therapeutic Uses of Sinalax

What Sinalax Treats: Main Uses and Benefits

Sinalax, which contains the active ingredients known as sennosides, is primarily used to address symptoms related to physical discomfort arising from episodic constipation. It is an established over-the-counter stimulant laxative commonly used to help with symptoms related to physical discomfort and temporary digestive issues.

The medicine is used for the relief of occasional constipation (irregularity). This application is common in clinical scenarios involving acute or unstable symptom patterns, and is relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden.

The use of this medicine is often employed when short-term symptomatic assistance is needed for situations where patients experience symptoms that interfere with daily functioning. By easing the overall symptom load, it assists with maintaining functional stability, which helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Occasional Constipation

Regulatory References

  1. Label: SENNA LAXATIVE- sennosides tablet, film coated - DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinalax? Official Eligibility

The eligibility profile for Sinalax (Sennosides) is determined by official regulatory bodies, defining specific populations who are permitted, restricted, or prohibited from using the medicine.


Contraindicated Populations

The medicine is strictly contraindicated and must not be used by patients diagnosed with intestinal obstruction, ileus, inflammatory bowel disease (such as Crohn's or ulcerative colitis), appendicitis, severe dehydration, abdominal pain of unknown origin, or undiagnosed rectal bleeding. Patients with known hypersensitivity to the active ingredient are also excluded.


Age and Clinical Status Restrictions

  • Adults and Children 12 Years of Age and Older are allowed standard labeled use for occasional relief. Use is established for children 2 to under 12 years.
  • Children Under 2 Years: Use is not established for over-the-counter use and requires consultation with a doctor.
  • Pregnancy and Lactation: Use is conditional. Patients who are pregnant or breastfeeding must ask a health professional before use.
  • Duration and Comorbidity: Use is restricted to a maximum duration of 7 days. Patients with stomach pain, nausea, vomiting, or underlying conditions such as heart disease or electrolyte imbalance must seek professional guidance prior to use.

What should I know about interactions with other medicines?

The interaction profile for Lactitol, the active ingredient in Sinalax, is predominantly characterized by effects occurring within the gastrointestinal tract due to its minimal systemic absorption. No systemic metabolic interactions, such as those mediated by the CYP enzyme system or major drug transporters, are officially documented in regulatory sources.

Pharmacodynamic Interactions

Co-administration with other laxatives or cathartics is formally documented to result in an additive pharmacodynamic effect, which increases the potential for undesirable fluid and electrolyte imbalance. Specifically, the resulting state of hypokalaemia (low potassium) is officially noted as one that can intensify the toxicity of co-administered cardiac glycosides, such as Digoxin. Hypokalaemia also increases the susceptibility to adverse effects from medicinal products known to induce Torsades de Pointes.

Exposure Modification and Administration Timing

Lactitol's osmotic action accelerates intestinal transit, which has a documented potential to reduce the systemic exposure of other orally administered medicinal products by diminishing their absorption. To manage this physical interaction, official product labeling requires a separation of administration between Lactitol and other oral medicines. No specific interactions with food, alcohol, or herbal products are documented in the regulatory labels.

Mechanism of Action

How Sinalax Works

Sinalax operates through two primary mechanistic domains within the gastrointestinal system to modulate fluid dynamics and colonic motility, resulting in localized physiological effects.

Modulation of Osmotic Pressure and Water Retention

Sinalax, or its primary active metabolite, functions as a non-absorbable solute, engaging physical mechanisms involving osmotic signaling within the colon lumen. This concentration gradient creates a hyperosmotic environment, driving an efflux of water from the surrounding colonic mucosa into the gut lumen. This influx of fluid subsequently modifies the viscosity and increases the volume of the colonic contents.

Pathway Modification via Microbial Metabolism

The unabsorbed agent reaches the distal colon where it is metabolized by the indigenous intestinal flora. This microbial metabolism yields short-chain organic acids, which modify the local colonic environment by lowering the pH. The resulting biochemical changes modulate signaling patterns and influence localized colonic motility.

Dosage and Administration Information

Administration Guidelines for Sinalax

Sinalax is administered via oral or rectal routes, depending on the specific formulation (e.g., tablet, powder, suppository, or enema). Adherence to the prescribed or package instructions is necessary to ensure correct use, as these products are primarily intended for short-term relief of occasional constipation.


Standard Administration Instructions

Administration Scope Description
Route of Administration Oral or Rectal
Dosing Schedule A single dose within a 24-hour period. Oral tablets are often recommended to be taken at night for a bowel movement the following morning.
Timing/Preparation Oral enteric-coated tablets must be swallowed whole and not taken within one hour of consuming antacids or milk. Powder forms must be dissolved in a specified amount of liquid prior to ingestion.
Age-Group Rules Rectal products containing active ingredients like sodium phosphate must not be given to children younger than two years. Specific dosing applies to children aged 6 to 12 years; consult a healthcare professional for children under 6 years.
Missed-Dose This is typically used as-needed. If a scheduled dose is missed, take it as soon as remembered, but do not double the dose to compensate.
Duration Constraint Do not use for a period longer than seven days unless directed by a doctor.

Procedural Summary

Proper dose preparation involves ensuring that coated tablets are not compromised by dairy or antacids to allow the drug to reach the intended site of action. The core procedural step is the administration of a single, measured dose, followed by a mandatory wait time of 24 hours before any repeat dosing. The entire use must be confined to a short-term duration.

Recent Clinical Evidence

Sinalax: Recent Clinical Evidence

Clinical evidence for Sinalax, which contains a type of laxative, is primarily centered on its use for conditions involving bowel function. Studies commonly examine two active ingredient classes associated with this brand name: osmotic agents (like lactitol) and stimulant agents (like sennosides).

Efficacy in Constipation

Randomized controlled trials (RCTs) have consistently supported the use of osmotic laxatives, such as lactitol, for chronic idiopathic constipation (CIC). Research indicates that this type of agent works by drawing water into the colon, which increases stool water content and volume, thereby facilitating bowel movements. The onset of this laxative effect is typically observed within a few days of consistent use.

Sennosides, a stimulant laxative, are also supported by evidence for the short-term treatment of occasional constipation. This class of drug works by increasing the contractile activity of the intestinal muscles. Comparative studies involving various laxative types suggest that both osmotic and stimulant agents show favorable profiles for improving bowel movement frequency and stool consistency in affected patients.

Other Observed Uses

Beyond general constipation, the osmotic class (lactitol) is also clinically indicated for portal systemic encephalopathy (PSE). In this application, the mechanism involves reducing the absorption of ammonia and other toxins in the colon. Clinical data show that adjusting the dose to maintain specific bowel movement goals is associated with positive outcomes in managing this condition.

Key Studies & References

  1. Lactitol for chronic idiopathic constipation: A systematic review and meta-analysis of randomized controlled trials
  2. Constipation - Clinical Guideline [NICE]

Frequently Asked Questions (FAQ)

Common questions about Sinalax (FAQ)

Q: What is Sinalax and how does it work?

A: Sinalax is a prescription medication indicated for the short-term treatment of severe chronic constipation when other treatments have not been successful. It is classified as a chloride channel activator. The exact way it works is complex, but it is thought to involve localized action on chloride channels in the small intestine, which may lead to increased fluid secretion and motility.

Q: Who is Sinalax indicated for?

A: Sinalax is indicated for adults with severe chronic idiopathic constipation (CIC). Its use has been studied specifically in this population. It is not generally used for occasional or mild constipation. The prescribing information specifies that a healthcare provider should determine its appropriateness for an individual patient.

Q: Is Sinalax effective?

A: Clinical studies have suggested that Sinalax may provide relief of constipation symptoms for some individuals with severe chronic idiopathic constipation. Evidence from randomized, controlled trials indicates that patients receiving Sinalax were observed to experience an increase in spontaneous bowel movements (SBMs) compared to those receiving a placebo. The degree of perceived benefit can vary between individuals.

Q: How does Sinalax compare to other laxatives?

A: Sinalax is a different class of medication than traditional over-the-counter laxatives. While comparative studies are limited, Sinalax is considered an option when standard treatments have not been satisfactory. Decisions about which medication is most appropriate should be made by a healthcare provider, taking into account individual circumstances and existing evidence.

Q: What are the potential adverse effects of Sinalax?

A: The most commonly reported adverse effects in clinical trials included diarrhea, nausea, and abdominal pain. Diarrhea was reported as the most frequent and was sometimes severe. Patients should be advised to discuss any adverse effects with their healthcare provider.

How should Sinalax be stored and disposed of?

How to Store and Dispose of Sinalax (Sennosides)

Official regulatory guidelines define specific conditions for storing Sinalax to ensure its stability and effectiveness, as well as proper methods for disposal.

Storage Requirements

The tablets must be stored at controlled room temperature, typically 25 C (77 F), with regulatory documents permitting excursions between 15 C and 30 C (59 F and 86 F). The medication must be stored in a dry place and protected from excessive humidity and heat. It is mandatory to keep the container tightly closed and store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Sinalax should not be disposed of by flushing down the toilet or by throwing into general household waste via wastewater. Authorities recommend using a local medicine take-back program as the preferred disposal method. If a take-back program is unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinalax found in:

A-Z Index: